A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/104582
Title:
A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.
Authors:
Anderson, Heather; Prendiville, Joseph A; Thatcher, Nick; Radford, John A ( 0000-0001-7898-2786 ) ; Swindell, Ric
Abstract:
159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1, 3, 5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P = 0.0007), and less nausea and vomiting (P = 0.03).
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. 1991, 117 Suppl 4:S139-40 J. Cancer Res. Clin. Oncol.
Journal:
Journal of Cancer Research and Clinical Oncology
Issue Date:
1991
URI:
http://hdl.handle.net/10541/104582
DOI:
10.1007/BF01613219
PubMed ID:
1665490
Type:
Article
Language:
en
ISSN:
0171-5216
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorPrendiville, Joseph Aen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorRadford, John Aen
dc.contributor.authorSwindell, Ricen
dc.date.accessioned2010-06-10T08:35:39Z-
dc.date.available2010-06-10T08:35:39Z-
dc.date.issued1991-
dc.identifier.citationA randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. 1991, 117 Suppl 4:S139-40 J. Cancer Res. Clin. Oncol.en
dc.identifier.issn0171-5216-
dc.identifier.pmid1665490-
dc.identifier.doi10.1007/BF01613219-
dc.identifier.urihttp://hdl.handle.net/10541/104582-
dc.description.abstract159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1, 3, 5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P = 0.0007), and less nausea and vomiting (P = 0.03).en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdministration, Oral-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshDoxorubicin-
dc.subject.meshEtoposide-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshSurvival Analysis-
dc.titleA randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalJournal of Cancer Research and Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.